Open AccessExpression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients
Author(s) -
Alaa Maria,
Mohamed El-Shebiney,
Ayman Mohamed Elsaka,
Yomna Zamzam
Publication year - 2018
Publication title -
journal of egyptian national cancer institute/journal of the egyptian national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.398
H-Index - 22
eISSN - 2589-0409
pISSN - 1110-0362
DOI - 10.1016/j.jnci.2018.05.001
Subject(s) - medicine , trastuzumab , immunohistochemistry , breast cancer , oncology , human epidermal growth factor receptor 2 , regimen , chemotherapy , hormonal therapy , cancer , hormone receptor , gastroenterology
The purpose of this work was to assess the truncated form of human epidermal growth factor receptor 2 (HER2) such as p95-HER2 expression in HER2-positive breast cancer (BC) patients who developed metastatic disease after adjuvant treatment with a trastuzumab-containing regimen.